These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 33427358)
1. The importance of smoking status at diagnosis in human papillomavirus-associated oropharyngeal cancer. Liu HY; Daniels CP; Trada Y; Bernard A; You KH; Brown E; Foote M; McGrath M; Ladwa R; Panizza BJ; Porceddu SV Head Neck; 2021 May; 43(5):1440-1450. PubMed ID: 33427358 [TBL] [Abstract][Full Text] [Related]
2. Impact of Smoking on Outcomes of HPV-related Oropharyngeal Cancer Treated with Primary Radiation or Surgery. Vawda N; Banerjee RN; Debenham BJ Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1125-1131. PubMed ID: 30513378 [TBL] [Abstract][Full Text] [Related]
3. Smoking cessation is associated with improved survival in oropharynx cancer treated by chemoradiation. Platek AJ; Jayaprakash V; Merzianu M; Platek ME; Cohan DM; Hicks WL; Marimuthu SP; Winslow TB; Gupta V; Arshad H; Kuriakose MA; Dibaj S; Marshall JR; Reid ME; Warren GW; Singh AK Laryngoscope; 2016 Dec; 126(12):2733-2738. PubMed ID: 27346612 [TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project. Lassen P; Lacas B; Pignon JP; Trotti A; Zackrisson B; Zhang Q; Overgaard J; Blanchard P; Radiother Oncol; 2018 Jan; 126(1):107-115. PubMed ID: 29100700 [TBL] [Abstract][Full Text] [Related]
5. Adverse effect of smoking on prognosis in human papillomavirus-associated oropharyngeal carcinoma. Liskamp CP; Janssens GO; Bussink J; Melchers WJ; Kaanders JH; Verhoef CG Head Neck; 2016 Dec; 38(12):1780-1787. PubMed ID: 27248701 [TBL] [Abstract][Full Text] [Related]
6. Impact of active smoking on outcomes in HPV+ oropharyngeal cancer. Xiao R; Pham Y; Ward MC; Houston N; Reddy CA; Joshi NP; Greskovich JF; Woody NM; Chute DJ; Lamarre ED; Prendes BL; Lorenz RR; Scharpf J; Burkey BB; Geiger JL; Adelstein DJ; Koyfman SA Head Neck; 2020 Feb; 42(2):269-280. PubMed ID: 31769100 [TBL] [Abstract][Full Text] [Related]
7. The declining role of post-treatment neck dissection in human papillomavirus-associated oropharyngeal cancer. Daniels CP; Liu HY; Bernard A; Williams C; Foote MC; Ladwa R; McGrath M; Panizza BJ; Porceddu SV Radiother Oncol; 2020 Oct; 151():242-248. PubMed ID: 32798595 [TBL] [Abstract][Full Text] [Related]
8. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. Oliva M; Huang SH; Xu W; Su J; Hansen AR; Bratman SV; Ringash J; Jang R; Cho J; Bayley A; Hope AJ; Chen E; Giuliani M; Waldron J; Weinreb I; Perez-Ordonez B; Chepeha D; Kim J; O Sullivan B; Siu LL; Spreafico A Eur J Cancer; 2019 Sep; 118():112-120. PubMed ID: 31330486 [TBL] [Abstract][Full Text] [Related]
9. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522. Bigelow EO; Harris J; Fakhry C; Gillison ML; Nguyen-Tân PF; Rosenthal DI; Frank SJ; Nair SG; Bahig H; Ridge JA; Caudell J; Donaldson C; Clifford BT; Shenouda G; Birrer MJ; Chen Y; Le QT Head Neck; 2022 Jan; 44(1):158-167. PubMed ID: 34729846 [TBL] [Abstract][Full Text] [Related]
10. Impact of smoking on stage-specific survival in human papilloma virus-associated oropharyngeal squamous cell carcinoma. Horwich P; Gundale A; Patin S; Flores J; Moore Medlin T; Chang BA; Nathan CO Head Neck; 2021 Sep; 43(9):2698-2704. PubMed ID: 34002904 [TBL] [Abstract][Full Text] [Related]
11. Survival advantage in patients with human papillomavirus-driven oropharyngeal cancer and variation by demographic characteristics and serologic response: Findings from Head and Neck 5000. Whitmarsh A; Pring M; Thomas SJ; Waylen A; Ness AR; Dudding T; Pawlita M; Brenner N; Waterboer T; Schroeder L Cancer; 2021 Jul; 127(14):2442-2452. PubMed ID: 33721332 [TBL] [Abstract][Full Text] [Related]
12. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. O'Sullivan B; Huang SH; Siu LL; Waldron J; Zhao H; Perez-Ordonez B; Weinreb I; Kim J; Ringash J; Bayley A; Dawson LA; Hope A; Cho J; Irish J; Gilbert R; Gullane P; Hui A; Liu FF; Chen E; Xu W J Clin Oncol; 2013 Feb; 31(5):543-50. PubMed ID: 23295795 [TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of additional HPV diagnostics in 102 patients with p16-stratified advanced oropharyngeal squamous cell carcinoma. Weiss BG; Anczykowski MZ; Küffer S; Spiegel JL; Bertlich M; Canis M; Ihler F; Kitz J; Jakob M Eur Arch Otorhinolaryngol; 2021 Jun; 278(6):1983-2000. PubMed ID: 32814982 [TBL] [Abstract][Full Text] [Related]
14. Smoking and other patient factors in HPV-mediated oropharynx cancer: A retrospective cohort study. Schostag K; Lynch PT; Leavitt T; Sumer BD; Yang A; Shah A; Emmet TR; Sher DJ; Day AT Am J Otolaryngol; 2022; 43(5):103555. PubMed ID: 36037765 [TBL] [Abstract][Full Text] [Related]
15. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. Huang SH; Xu W; Waldron J; Siu L; Shen X; Tong L; Ringash J; Bayley A; Kim J; Hope A; Cho J; Giuliani M; Hansen A; Irish J; Gilbert R; Gullane P; Perez-Ordonez B; Weinreb I; Liu FF; O'Sullivan B J Clin Oncol; 2015 Mar; 33(8):836-45. PubMed ID: 25667292 [TBL] [Abstract][Full Text] [Related]
16. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer. Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347 [TBL] [Abstract][Full Text] [Related]
18. HPV status and therapeutic initial strategy impact on survival and oncologic outcomes: 5-year results from the multicentric prospective cohort of oropharyngeal cancers Papillophar. Culié D; Rousseau A; Pretet JL; Lacau Saint Guily J Eur Arch Otorhinolaryngol; 2022 Jun; 279(6):3071-3078. PubMed ID: 34661716 [TBL] [Abstract][Full Text] [Related]
19. 20 pack-year smoking history as strongest smoking metric predictive of HPV-positive oropharyngeal cancer outcomes. Chen SY; Last A; Ettyreddy A; Kallogjeri D; Wahle B; Chidambaram S; Mazul A; Thorstad W; Jackson RS; Zevallos JP; Pipkorn P Am J Otolaryngol; 2021; 42(3):102915. PubMed ID: 33482566 [TBL] [Abstract][Full Text] [Related]
20. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]